00:46 , Apr 28, 2018 |  BioCentury  |  Strategy

The outsiders

As he retires from Sanofi, Elias Zerhouni has advice for the biopharma industry: the traditional executive mold must be expanded. On April 24, Sanofi announced Zerhouni would retire on June 30 and that John Reed,...
22:56 , Apr 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Cell culture and mouse studies identified p53-activating tetrahydroindazole-based DHODH inhibitors that could help treat melanoma. Screening of a small molecule library in human melanoma cell line-based assays of p53-dependent transcription, followed by chemical...
21:34 , Feb 28, 2018 |  BC Extra  |  Financial News

Celgene's slide continues after refusal to file letter

Celgene Corp. (NASDAQ:CELG) shed $8.66 to $87.12 on Wednesday after FDA issued a refusal to file letter for an NDA for ozanimod (RPC1063) to treat multiple sclerosis. The news was announced after market close Tuesday...
01:40 , Jan 27, 2018 |  BioCentury  |  Strategy

Growing up Genzyme

The proposed acquisition of Bioverativ Inc. ticks multiple boxes on Sanofi’s to-do list for transforming itself into a top tier pharma, and solidifies the position of its Genzyme unit as the pharma’s growth engine. Olivier...
22:30 , Apr 14, 2017 |  BioCentury  |  Emerging Company Profile

Tolerating DHODH

Immunic AG is betting on the tolerability and efficacy of its oral, next-generation dihydroorotate dehydrogenase inhibitor to differentiate it from first-generation agents and give it an edge over other types of oral therapies in the...
01:03 , Feb 16, 2017 |  BC Innovations  |  Emerging Company Profile

Autoimmunity alternative

Inhibiting the nucleotide biosynthetic pathway in autoimmune diseases is one way to avoid the risks of broad immunosuppression, but the marketed compounds have serious side effects of their own. Step Pharma is pursuing a safer...
07:00 , Oct 28, 2016 |  BC Extra  |  Financial News

Sanofi gains despite complete response letter

Sanofi (Euronext:SAN; NYSE:SNY) shares rose Friday after the company reported earnings showing growth of its multiple sclerosis drugs, combined with double-digit gains from its vaccine business and rare disease portfolio, are offsetting continued headwinds in...
07:00 , Oct 20, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML) Mouse studies suggest inhibiting DHODH could help treat acute AML. In two mouse models of AML, a DHODH inhibitor tool compound increased survival and the levels of markers of differentiation...
07:00 , Oct 26, 2015 |  BC Week In Review  |  Clinical News

Aubagio teriflunomide: Additional Phase III data

Additional data from the double-blind, international Phase III TEMSO trial in 1,088 patients with relapsing MS showing that once-daily 7 and 14 mg oral Aubagio each led to significantly lower median percent reductions in brain...
01:44 , Sep 11, 2015 |  BC Extra  |  Company News

SSR report links PBM exclusions to cresting drug prices

A report from investment research firm SSR Health found that after rebates and discounts, the net price of U.S. branded prescription drugs grew by 0.7% year over year in 2Q15, compared to a 4.4% increase...